<SEC-DOCUMENT>0001193125-26-337974.txt : 20260806
<SEC-HEADER>0001193125-26-337974.hdr.sgml : 20260806
<ACCEPTANCE-DATETIME>20260806160820
ACCESSION NUMBER:		0001193125-26-337974
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20260806
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260806
DATE AS OF CHANGE:		20260806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Trevi Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001563880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				450834299
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38886
		FILM NUMBER:		261248991

	BUSINESS ADDRESS:	
		STREET 1:		195 CHURCH STREET
		STREET 2:		16TH FLOOR
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203-304-2499

	MAIL ADDRESS:	
		STREET 1:		195 CHURCH STREET
		STREET 2:		16TH FLOOR
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>trvi-20260806.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-08-06T10:14:52.6909+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:trvi="http://www.trevitherapeutics.com/20260806" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_010c86df-6375-402b-8fff-cf24a014cb3b" name="dei:AmendmentFlag" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_443e78a6-97ae-49b2-b079-3daa0f3f52bc" name="dei:EntityCentralIndexKey" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f">0001563880</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="trvi-20260806.xsd"/></ix:references><ix:resources><xbrli:context id="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563880</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-06</xbrli:startDate><xbrli:endDate>2026-08-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88b72521-18a8-42e3-8cf5-3f60712d086c" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6b0b947-29aa-4329-8de7-623a95b84ed1" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 6, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8d13245-a1d4-4295-bc51-6f00603701fb" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:38.44%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3fe60d15-d48e-41b6-86bb-720ea8f22ab2" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f0dbe610-88f6-4139-98c0-a5c4d67188ab" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-38886</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b98e9ed8-2493-4bde-b1c0-51f24a046f08" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">45-0834299</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of Incorporation)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File Number)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39%;box-sizing:content-box;"/>
     <td style="width:22%;box-sizing:content-box;"/>
     <td style="width:39%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;"><ix:nonNumeric id="F_90a2c64b-12eb-4b80-b27a-e6cd914396cd" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">195 Church Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;"><ix:nonNumeric id="F_1359e679-dc46-4432-bce7-1b3be6c375ff" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> Floor</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_f0529c0c-8305-46f2-8f14-3f47d2b35d6a" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New Haven</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_224947f6-127f-4003-a913-250aeb75e47c" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Connecticut</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a63acce3-2eac-4093-971e-eaf0f60875bd" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">06510</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d76ada8-873d-4de4-b51f-d65c12d77b80" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(203)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c98a87b-6b3b-479b-9000-4f6ce639c9d5" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">304-2499</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_69161118-9ceb-4a6a-8b95-feeee4a2cafc" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4868c66a-146a-4992-a381-51a71c78ee0f" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_bcfe3931-80d5-4bb7-8699-d74cd7cea4e5" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_1e54c2c1-0d3c-4566-93e6-013d823a4d5b" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:39%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_26fdd185-e141-45ee-8f10-deb61b17ccf9" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7536ceda-08b6-4dfa-bcac-029d866409af" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRVI</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4a816194-d16a-4034-9994-146c06aa86f0" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company  </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0e60ef11-a67e-40c3-b30c-3d14afe3c103" contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.69in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 6, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), announced its financial results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information provided under Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01. Financial Statements and Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8.362%;box-sizing:content-box;"/>
     <td style="width:1.06%;box-sizing:content-box;"/>
     <td style="width:90.578%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="trvi-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press release issued by the Company on August 6, 2026</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    </tr>
    <tr style="height:5.05pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	The exhibit shall be deemed to be furnished, and not filed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.69in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:44.969%;box-sizing:content-box;"/>
     <td style="width:9.962%;box-sizing:content-box;"/>
     <td style="width:4.001%;box-sizing:content-box;"/>
     <td style="width:41.068%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TREVI THERAPEUTICS, INC.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 6, 2026</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ David C. Hastings</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: David C. Hastings</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Chief Financial Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.69in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>trvi-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-08-06T10:14:52.7459+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img251553556_0.jpg" alt="img251553556_0.jpg" style="width:216px;height:129px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth quarter of 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Management to host a conference call and webcast today at 4:30 p.m. ET&#x202f;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">New Haven, Conn., August 6, 2026</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> &#x2013; </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational&#x202f;therapy&#x202f;Haduvio&#153;&#x202f;(oral nalbuphine ER)&#x202f;for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),&#x202f;and refractory chronic cough (RCC), today announced financial results for the quarter ended June 30, 2026, and provided business updates.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We are on track with our clinical trial plans as we initiated&#x202f;our&#x202f;first Phase 3 trial&#x202f;of&#x202f;Haduvio&#x202f;in patients with IPF-related chronic cough and a Phase 2b trial in patients with RCC&#x202f;during the second quarter. We expect to initiate our second&#x202f;Phase 3 trial&#x202f;in IPF-related&#x202f;chronic cough during the third quarter and meet with the FDA regarding our&#x202f;planned&#x202f;non-IPF&#x202f;ILD-related chronic cough&#x202f;trial,&#x201d; said Jennifer Good, President and CEO of Trevi Therapeutics. &#x201c;With&#x202f;an experienced team&#x202f;dedicated&#x202f;to advancing&#x202f;our trials across all three of our chronic cough indications, and&#x202f;a strong balance sheet following our&#x202f;April&#x202f;financing, we&#x202f;are&#x202f;well positioned to execute on our plans. We recognize the significant unmet need these patients have and are working diligently to enroll our trials. Following the recent changes in the competitive landscape, and with no FDA-approved therapies currently available, Haduvio has the potential to become a first-in-class therapy that makes a meaningful difference in patients' lives.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Recent Business Highlights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IPF-Related Chronic Cough</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company initiated the </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Phase 3 OCEAN-1 trial</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, the first of two parallel conducted Phase 3 trials in patients with IPF-related chronic cough, in the second quarter of 2026. Topline data from the 52-week fixed dosing OCEAN-1 trial is expected in the first half of 2028.&#x202f;The Company plans to&#x202f;initiate&#x202f;the&#x202f;12-week fixed dosing OCEAN-2 trial, in the third quarter of 2026, with topline results expected in the second half of 2027.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Non-IPF ILD-Related Chronic Cough</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company recently submitted a meeting request to the FDA to discuss the proposed development plan for non-IPF ILD-related chronic cough and to align on the overall regulatory </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">strategy and requirements to support registration.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Refractory Chronic Cough</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company initiated the </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Phase 2b LAKE trial</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> in patients with RCC&#x202f;in the second quarter of 2026. The protocol includes a sample size re-estimation (SSRE) analysis&#x202f;once 50% of the participants complete&#x202f;treatment which&#x202f;is&#x202f;expected to occur in the fourth quarter of 2026.&#x202f;The&#x202f;Company will report the&#x202f;outcome&#x202f;of&#x202f;the&#x202f;SSRE&#x202f;once&#x202f;available&#x202f;and&#x202f;expects&#x202f;to report&#x202f;topline results from the trial in the second half of 2027.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Second Quarter 2026 Financial Highlights&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> The Company ended the second quarter of 2026 with $318.9 million. In April 2026, the Company </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">completed an underwritten common stock offering</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, resulting in net proceeds of approximately $162.3 million, after deducting underwriting discounts, commissions and offering expenses.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company expects its current cash, cash&#x202f;equivalents&#x202f;and marketable securities to&#x202f;extend&#x202f;its&#x202f;cash runway into 2030 and&#x202f;fund the development of&#x202f;Haduvio&#x202f;for the treatment of patients with IPF-related chronic cough, through potential FDA approval. The Company also expects these cash resources will enable the Company to fund&#x202f;the&#x202f;clinical&#x202f;development program through Phase 3&#x202f;for&#x202f;the treatment of patients with non-IPF ILD-related chronic cough, and the ongoing Phase 2b LAKE trial for the treatment of patients with RCC. The planned spending of these resources does not include any commercial expenses related to the commercial launch of&#x202f;Haduvio&#x202f;or&#x202f;a Phase&#x202f;3&#x202f;clinical trial in RCC.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development (R&amp;D) expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> R&amp;D expenses for the second quarter of 2026 increased to $15.2 million from $9.4 million in the same period in 2025, primarily due to increased clinical development expenses for the Phase 3 OCEAN-1 trial, the Phase 2b LAKE trial, the Phase 3 OCEAN-2 trial and the Phase 1 NDA supportive studies, as well as increases in stock-based compensation and personnel related expenses. These increases were partially offset by decreased costs for the Phase 2b CORAL trial of Haduvio for patients with IPF-related chronic cough.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative (G&amp;A) expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> G&amp;A expenses for the second quarter of 2026 increased to $5.4 million from $4.3 million in the same period in 2025, primarily due to an increase in stock-based compensation and personnel related expenses, partially offset by decreased outside services and professional fees.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other Income, net: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other Income, net for the second quarter of 2026 increased to $2.7 million from $1.4 million in the same period in 2025, primarily due to an increase in interest income from higher invested cash equivalent and marketable securities balances.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">For the second quarter of 2026, the Company reported a net loss of $17.8 million, compared to a net loss of $12.3 million in the same period in 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Conference Call and Webcast</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company plans to hold a conference call and webcast to discuss the Company&#x2019;s financial results and business highlights. To register for the live conference call and webcast, please visit the &#x2018;Investors &amp; News&#x2019; section of the Company&#x2019;s website or access directly at&#x202f;</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ir.trevitherapeutics.com/news-events/events</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">archived replay of the webcast will also be available for&#x202f;30 days&#x202f;on the Company's website following the event.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Upcoming Meetings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company plans to participate in the following events:&#x202f;&#x202f;&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">August 10-12: Stifel&#x2019;s 2026 Biotech Summer Summit</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">September 9-11: 2026 Cantor Global Healthcare Conference</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">September 14-16: H.C. Wainwright 28th Annual Global Investment Conference</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">September 14-16: Morgan Stanley 24th Annual Global Healthcare Conference</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Trevi Therapeutics, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio&#153; (oral nalbuphine extended-release)&#x202f;for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).&#x202f;In clinical trials, Haduvio&#x202f;showed&#x202f;a&#x202f;statistically-significant&#x202f;reduction in cough frequency,&#x202f;consistent across baseline&#x202f;cough frequencies,&#x202f;and&#x202f;showed&#x202f;improvements&#x202f;in patient-reported outcomes,&#x202f;in both&#x202f;patients&#x202f;with IPF-related chronic cough and in patients with RCC.&#x202f;Haduvio&#x202f;is believed to&#x202f;act&#x202f;on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Chronic&#x202f;cough&#x202f;in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting &gt;8&#x2005;weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip)&#x202f;and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and&#x202f;may&#x202f;impact&#x202f;patients&#x202f;physically, psychologically, and socially.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">For more information, visit&#x202f;</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.TreviTherapeutics.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;and follow Trevi on&#x202f;</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">X</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;(formerly Twitter) and&#x202f;</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.&#x202f;&#x202f;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> &#x202f;<br>Statements contained in this press release regarding matters that are not historical facts are &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi&#x2019;s estimated cash runway, statements regarding Trevi&#x2019;s business plans and objectives, including future plans or expectations for Haduvio and plans and timing with respect to clinical trials and clinical data, as well as regulatory submissions, statements regarding FDA guidance and approval, and expectations regarding Trevi&#x2019;s uses and sufficiency of capital, and other statements containing the words &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;may,&#x201d; and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties inherent in estimating Trevi&#x2019;s cash runway, future expenses and other financial results, including Trevi&#x2019;s ability to fund future operations, including clinical trials; uncertainties regarding the success, cost and timing of Trevi&#x2019;s product candidate development activities and clinical trials, including with respect to the timing of the initiation of and generation of data from clinical trials; the risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials in the same or a different indication; uncertainties regarding Trevi&#x2019;s ability to execute on its strategy; uncertainties with respect to regulatory authorities' views as to the data from Trevi&#x2019;s clinical trials and next steps in the development path for Haduvio in the United States and foreign countries; as well as other risks and uncertainties set forth in the annual report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:1pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Selected Balance Sheet Data</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(amounts in thousands)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.633%;box-sizing:content-box;"></td>
     <td style="width:1.52%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:13.163%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.52%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:13.163%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">June 30,<br>2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">December 31,<br>2025</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">54,302</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">18,914</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Marketable securities</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">264,568</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">169,346</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Working capital</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">316,969</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">181,907</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">330,518</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">193,439</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Stockholders' equity</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">321,506</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">183,244</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Selected Statement of Operations Data</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(amounts in thousands, except per share amounts)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.77%;box-sizing:content-box;"></td>
     <td style="width:1.02%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.198%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.14%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.198%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.14%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.198%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.14%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.198%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Three Months Ended<br>June 30,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Six Months Ended<br>June 30,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">15,152</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">9,389</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">25,093</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">17,200</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5,357</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">4,333</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">10,328</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7,992</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">20,509</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">13,722</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">35,421</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">25,192</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(20,509</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(13,722</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(35,421</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(25,192</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other income, net</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2,693</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1,400</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">4,393</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2,519</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Loss before income taxes</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(17,816</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(12,322</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(31,028</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(22,673</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Income tax benefit</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(19</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(21</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(39</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(32</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(17,797</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(12,301</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(30,989</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(22,641</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share outstanding</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.11</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.09</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.21</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.18</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">156,602,158</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">130,350,391</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">151,127,942</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">124,015,763</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investor Contact</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Jonathan Carlson</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(203) 654 3286</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IR@trevitx.com</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Media Contact</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Rosalia Scampoli</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">914-815-1465</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">rscampoli@marketcompr.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img251553556_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img251553556_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $H >\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHIXQ+!(KJW*LIR#2'<=11D=<T9% !1110 4444 %%%% !1110 4444 %%%%
M!2%EZ9I:_/\ _P"#C3X]?&K]G;]B3P_XW^!'Q4U[PCK$_P 1+.TFU+P_J4EK
M,\#6EXS1ED()4LBDCIE1Z5TX/#2QF*A0B[.3M<Y,?C(8#!SQ$U=15[(_0#</
M6C</6OY3Q_P5/_X*1X_Y/C^)_P#X6%U_\71_P]/_ ."D?_1\?Q/_ /"PNO\
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M_CE>E_L=?\'%_P"T-^TI^U+X#^ GB/X >#=-L?%WB:VTRZOK&ZNVF@CD;!9
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MVT^3/SCCS.N)\BSSDP^(DJ51*459:=&M5T:OZ-'Z6I_P<R?M*-_S;CX']O\
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M_9_\&_\ @9=__%U(G_!P_P#M"2?\T!\&C_M[N_\ XNOSUA@)Y?\ _55B./\
MSZU]L^'<EV5%?>_\S\XCQ5Q'N\0_NC_D?H0G_!PU^T"QP?@%X._\#+K_ .+K
MUK]B7_@KO^T=^U]^T?H/P4A^"OA>QLKTRW&L:E;S73M:6D2%W?EL DA8USQO
MD7-?E)%'CDK7ZJ_\$!/V>FT#X?>*/VE=:T\K<:]=?V1H<K?\^D)W3L/9IMJ_
M6 UY&=99DN7Y;.K&DN;9:O=_/IO\CW^'<XX@S;-Z="5=\M[RT7PK5].NWS/T
M \:>(?\ A#_!VK>+3:FX&EZ;<7A@\S;YGEQL^W.#C.,9P<5^>*?\'"VC.N?^
M&6;K_P *U?\ Y&K[\^-7_)&_%O\ V+-__P"D[U_.G%&QZ"O$X7RO YC3JO$0
MORM6U:WOV:/IN,<ZS+*JM%86?+S*5]$]K=T^Y^F@_P"#A#16X'[+=U_X5B__
M "-4B_\ !P1HN.?V7[K_ ,*Q?_D:OS/CC"BI43=Q7T_^K.2]*7_DTO\ ,^._
MUOX@6];_ ,EC_D?I:O\ P<"Z*W3]E^Z_\*I?_D>ON+]G'XQ)^T!\#_#?QFBT
M%M+7Q#IXNET]KCSC!EB-N_:N[IUP*_GWAAK]T/\ @F^,?L-_#48_YEU?_1CU
M\YQ-E.7Y?A83P\+-RMNWI9]V?6<(YWFF:8V=/$SYDHW2LEK=+HD>W4445\6?
M?A1110 4444 %%%% !1110 4444 %%%% '\^O_!TC_RD6T'_ +)7IW_I=?U^
M;H!;J>*_2+_@Z1(/_!1?003_ ,TKT[C_ +?;^OS?7!^\?PK]@R/_ )%-'_"C
M\%XD_P"1YB/\3!5[D5*D9)S0D9/-2HG. *]8\"4@5.P-2*N.!0!V J1$ .36
MBB82D(B<\U?T7P]KOB*Z^P>'M&NKZ?'^JL[=I& ]2%!P*LZ=KFBZ1MDMO#%O
M>3#[TFIR-(F?41H4'X,7%7[SXM?$&[LCID/B::RL^GV33%6UBQZ;8@H_.A\_
M1 O9[R?W']5G['UI=6'[)GPQL+Z!HIH/A]HT<T;=486,((/N#7S#_P '",/@
M"7_@GXQ^)5Q<QZ8OC?2R?LH.]Y,387@$XZ^GUKZ;_8V=Y/V1/A;(\A9F^'>B
MEF8Y)_T&'FOF+_@X6\!Z_P#$C_@GRWAGPZ;=;AO'&ER;KF0JH4";)R ?7TK\
M=R^W]N0N[>_^I_0&;7_U:J\JO^[V^1^'ME\6_P!FWP>=GA3X.R7CK]V:_C1L
MGUW2M(1^0JQ=_MF:U!%]E\.> +&UB'W4FN6<+^"A*L^'_P!BG4)$63Q+XXAC
M;^.'3[4OQ_ON5_\ 0:Z.W_9Q_9^\+R*FO:U+<S?\\;[5E4M]$C"G^=?J3E@5
MO>7WL_#5',N72T%\D><ZC^UI\7[QB;2XTZS']VWL0W_HPM69-\??C9KDGE#Q
MM=EV_P"6=G;QQG_R&@KZ&T#X;_""QVRZ#\-X)B!\LTFELWY-.!G\#BNNL+6T
MM(%CL],CM4'2..-5Q^"\5/UC#Q^&G]]@^J8JI\59_*__  #Y.A/[17B/YX9/
M&5RC_P 2M=;#_P"RU:MO@M^T!KA^?P[JC;OXKR^"?^C'%?6*J7/4U?M?#7B*
M[T]]4M- OI+6-<R74=J[1J/4L!@#\:?UZ4=HI!_9<9?%.3_KYG=?\&[/P5^(
MG@+]O:_\0^*M)CMX6^'>HQ[_ +9'(Q8W-GQA2?\ (^E?M%\6OBAX2^#'PWU?
MXH>.=1%MI>BV;7%U)_$W0+&H[N[%44=V8#O7Y>_\$5/%OAC4OVT;[1=/\0V-
MQ>1^![\O:PW2-(H%Q:9) .>*Z#_@N'^WE\/=+^(NG_LH#QW%;KH4<>I>)K5(
MY&+74J9MXFVJ1A(F\S'<RJ>JBOB,VPM;-N(%3M]E-V71?U8_2LAQ^&R'A&5:
M_P!J25WO)VM]V[\DSX2_;CO_ -I;]O'X]ZA\:OB=XMTFWMV8P>'M!CNIGATB
MQ#$I G[L M_$[X!=R3P, >1+^QIXX4\^*])Y_P"NO_Q->F_\-,?!I.GBEG_W
M+&;_ .(IJ_M._"$G)U:\_P#!=)_A7W%#ZUAZ4:=.%HI62L?E^*^HXJO*M6J<
MTI.[;ENSSA?V-_''3_A*M(_\B_\ Q-(W['/Q &5B\1:,W_;249_\AFO2U_:<
M^$+D#^VKI5_O'3Y<?RKI/AI\2O#?Q@\76?P_^%MMJFO:UJ$FRSTO2]%N9II#
MZA5C)P.Y/ ')(%:2Q.-A%MK1>1S1P>65)*,'=O9)ZL\*F_9%^)UO_J+K2)O]
MRZ<9_P"^D%,7]G#XYV'_ !Y6:\=/L^K(O\V%?IQX0_X)$_MB>*-.BU*_L/#>
MA^8N?LNL:TWG+QW6"*51^+9'I5?QY_P2B_;%\":7)JUKX8T;Q#'$,M#X=U8R
M3;?79,D18^R[C7GQXBPO-RNK!OU_X)ZTN"\=[/G]A42]'^5KGYH/\._VG- '
M[E?$"A>UGK!<?DDAI(_%'[3OA[Y[A_$R*O\ %<V+RJ/Q="*^IM3TO4]$U:XT
M'6M-GL[ZUE,5U9W4+1RPN.JNAPRD>A -0M'<!2T 4D=F8C]<&O06.YE[T$SQ
MI97ROW:DE\_^&/F6V_:5^,NES!-1U2"1OXDN]-C3/_?*K7MG['__  56^,/[
M*GQ7LO'=EX8L;W2Y62'Q#I-O/)$NH6N?F7DL!(O+(^/E;_99@>DNC=O"RZAX
M96Z7O'!+')N_[^;!7.ZMX9^$%YF3Q1\.%M?[TLFB.N/^VD*D#_OJBI+!8FFZ
M=6BFGNE_P+%4*>:8&M&K0Q#4HNZ;7^=_F?OO\(?BQ\/_ -H3X3Z+\6OAUJL>
MI^'O$FFI=6,Q7[T;CE'4_==3E'0\JP93R#7X4?MV?LV?LU_L[?M3>+/@KJUE
M>Z"UO??:=*F@CF6-[.=1+$4R'0A0WEDX W1MZ5]N?\$.OVA/AWX8O-6_94T'
MQ7:R65\TFK>&[/\ M/S?*G 'VF!%9BPW*/-VC@%)3U)J;_@O?^Q/_P +=TSP
MK^TKX6N8;74M)5M$UN26-F6:V=C);%B/NA)#,N<')G4=J^'RG_A&SZ>%G)J$
M]GMYQ;_%>I^J9\O]9N%*>.A",JE/XENNTTNW22\D?F"_[//A76/F^'OQ<TJ]
M8_=M[J10_P":$G_QT5A^(/@A\3?"P+ZCX4GFB'_+:R_?KCU.S) ^H%:&K_LV
M?%/1@7BT:"_5>=UA<!OT?:WY"LVUU3XF^ ;CR!J.L:2R](9&DC7_ +Y;@_E7
MZ#&<Y?!44O7_ ('^1^4RI4J?QTG'TV_'_,Y^.$E]K _+QMK]1?\ @W._: %E
MJ_CC]F'5[\[;J./Q#H<#?=5TVP78'N0;8@>B,?7'YW3?%;6-;"P^,= TG6AC
M'G75GY<X'M)$5(_6O5/V$?CMX-_9V_:X\$_%ZS?4M)M;;64M=6MY)%N(FL[@
M>3-EQL8!4<N 5;E!DBN#.L++'994HN.MKJVNJU7GKMMU/:X<Q4<LSJCB%+2]
MG?3W7H_+2]]^A_0H**1"&165LC'!]:4G S7XN?T4?'O_  6Z^.P^$7[$^I>#
M]/O?+U3QW?1:+;HI^8VYS+<GZ>6GEG_KJ*_$F&+!_P \5]U?\%Z?CL?B)^U1
MIOP;TV[9K'P'HJK=1_PB^NPLTA_[\_9A]0U?#J1].*_6N%\)]4RF+:UG[S^>
MWX)'X7QEC?KV?3L[QI^XOEO_ .3-_<$<9(S5B./'-$<1!R>M6(XLGYA7T!\O
M:Y<\+>&-:\7^(]/\)^';&2ZU#5+Z*TL;:-<M--(X1%'U8@?C7]#W[.?P8T7]
MGOX'>%_@SH+(\/AW1X;62XC3;]HF S+,1ZO(7<^[5^3G_!%+]GH?%W]K6/XA
MZQ8^;I?@*Q_M%V/W?MKDI;*??/F2#WAK]F5&T8S7YUQECO:8B&%B](J[]7M]
MR_,_6N ,M]CA:F,DM9OE7HM_O?Y',_&K_DCGBW_L6;__ -)WK^=R- %]*_HC
M^-'_ "1WQ9_V+-__ .D[U_/#&A;M73P7_!K>L?U.7Q _C8?TE^:!(]^#VJ:*
M+=@D4Z*'U6K447K7VY^>Q5M1L4)SDC_ZU?N1_P $Y./V'_AN/^I=7_T8]?B!
M'%GKP*_<'_@G2"/V(_AP,?\ ,O+_ .AO7Q_&7^XT_P#%^C/NN _^1E5_P?JC
MVJBBBOSH_5 HHHH **** "BBB@ HHHH **** "BBB@#DO&OP$^!OQ*UA?$/Q
M'^#7A3Q!?I L"7VM^';:ZF6,$D('E1F"@LQ S@%CZFOSB_X.0OV;OA;X2_8A
M\.WOP9^ GA_3-4F^)5E"\WAGPM!#.\9L[TE"T$8;;D D'CCVK]2J_.K_ (.9
M_%WB7PA^P/H<_AK5)+.6Z^)%E%)/"V'V&SO20#VSCJ.:]C(ZE;^U*,4_M+2^
MAX/$E&A_8N(E**^%ZV5S\)9O@MK/AZW6Y^(FO:;X>5E#+;WEQYMTX/I!%N?_
M +ZV^^*S+E_A_IK>7I=KJ&JR+_RVO&6VA;_MFA9R/^!J:QY9)[J5I[F9I)';
M,DDC$LQ]2>]=G\.O@/\ $/XC[;O2-*^RV+?\Q"^S'&?]W@L__ 01ZD5^N6Y8
M\U27Z'X+?VDN6E']7_E^!RD]S]H'EQ6<$*!LJD,?3_@3$L?Q)KU[_@G_ .#Y
M?&7[:OPGTJ?PO_:VGM\2-%75+>2Q\^!H#?1!Q*I!785R"&X(ZUW7A']EGX8>
M"K3^U_&E[_:DD*[I9KV00VR>^T'_ -"8CVKT[]DS]H7X6Z5^U_\ "GP)X'M/
MMAN/B-HMNGV"$16L.Z^B!.<#=C/\((/K7'B<5S8>:I1;T>OR.[!X/EQ=.5>2
M7O+3YH_>H?LD?LJ8Y_9E^'W_ (1EC_\ &J:W[(W[*IZ?LS?#W_PC+'_XU7H@
MSCFBOQSV]?\ F?WL_H3ZMA_Y%]R(-,TS3]%TZ#2-)L8;6UM85BM;:WB"1PQJ
M %15'"J   !P *^0O^"Y&F^)M5_8@:T\*>(8]+N3XPTTM>26:S;4_>Y 5N,]
M.M?8E?#'_!PSXZU_X>_\$]9M>\-31QW3>--,A626,/L#";) /&>.^:[<IC*6
M:44M^9?F>;G\HT\EQ$I;*#V]#\H$^%.DQQM?>./&FM:P%^:8W^J-#;C_ +91
M%$Q['-9M[\9O@%\-5:TT:^T_S /FAT.S5]WU= $S]6S7@\>B_&SXR7 O'M=8
MU@$_+--E8%^A;"+^%=1I?[*'B.PA&J>//&FD:' O.YIO,93^.U?R8U^L_5Z<
M?XM3Y+^OT/P/ZY6GK0I?-_Y_\$ZO4?VN;W4%8^"OAQ/-&IQ]JU"?:B^[;1@?
MBXKG-4_:"^*M_*RW7CK0=%C9>$L8!<L!]567!^K TL^A?LN^&@K>(/&^L>))
MT^]'9Y\L_3 48^CUL_"[X@_!?5?BAX<\%>%_@79F'5=>L[)KK5)@SA99T0G!
M5R.&[-6JIT8Q<HTV_5?Y_P"1SRK8B<E&=5)OHG_\BOU/U=_X)#_\$FO"T/PM
MT7]JC]K6^OO&6N>)+./4/#OAG72W]GZ99R+NAEEM2Q2::1")/W@*HK*-@<$U
M^D=AI]EI=I'8:=9QV\$2A8X88PJ(H[ #@#Z4:=9VNGV45A8VZQ0P1K'#&BX5
M%48  [  5-7XYC\=B,PQ#JU'Z+HEV2/Z*RO*\+E.$C0HQV6KZR?5M[N_X;(X
MJZ^"_P #O"_Q N/VA%^&N@V/BBVTFXM[KQ1;Z='#=O:-MDD2250#(N8E;YLX
M*\8YK^>/XZZC^TY\;_C;XJ^-.MZ7X9TZ?Q-KUSJ&+FQLGDBCDD+1QEVC=B$3
M:H)).%%?O#_P4EU?4-)_85^*"Z1JBV5YJ'A*YTVUNF)'EO= 6X88YR/-X]Z_
MGY@_8W<X?5OB4W^UMT_^K25]CP?&/LZE>I+72*NF]%KI]Z/SGQ$J5/;4<-2@
M[:S=FHW;T3>FKT?WC!X)^.P7;=?%3PS9\ ;5FBCQ[?)#3AX1^,;#RY?V@_#J
MG/S#^U!G_P!%BK4?[+7PGL>-:^)4RXX_X^K>+G_@0-*WP"_9WA7,_P 3'Q_V
M&+;_ .(K[3VE/H__ "4_,94:W56]9L@7P?\ &B>3R;;X]>'YF/&U=2!)]L>6
M<U^[?_!,7]ARU_8\^ .FKXT%MJ/Q"URU6Y\6:W]E19(W<!A91D#(ABX7' =P
MSD#< /Q5^"?PB_92\,_&/PGXM\6_$%IM'TOQ+8W>J0'5+>02V\5PCR(5"@G*
M*1@$$YZCK7[+VO\ P66_85NCMM/'FI3>GE:66_DU?)\5?7:].%##P;B[N5HV
M[66GW_<??<!?V7@Z]3%8RI&,U91O.^^[2?797]>Y]5B@\C%?,*?\%=_V-I>8
M]<\0-[KH,G^-._X>X?L>$9&M:_\ CH,G^-?$?V7F7_/J7W,_4O[>R7_H(A_X
M$CR?_@MS^P!X#^-GP1U3]J7PCX5NH_'/@FQ^U7UQH4@AN-6TQ!^]CD^5O,:)
M,RH2-P5&0'# #\8]-^(M[I4_EZ/\6/%&GLO_ "PU:'[1&GMQ(?\ T"OW.\??
M\%A/V.I_#>HZ)?Z;XUFCO+&:!FM_"C3J0Z%3D(YXP>]?B8?VAO'%O<MIOBWP
MGI-_%&VWR]0TUHY&7WYP#C_9K]%X4_M"&#E1Q$':+7+?L^BNGHFOQ/QKC[^Q
MZF94\3@ZJYII\W+KJK6;LTTVG\[%[0OCM\4;>1GC\2^'==C7KY^+5S] _E9/
MT!KK-+_:BCLV2/QG\/\ 4+'<<>?;MN1O<!PN1]":XZV^(GP,\0GR_$_P:^PY
MZS:3<<Y^@,?]:U-/\(_ 76DV^#_BGJ&AS2?\L=2'R_0Y"@_]]'\:^@J0HOXZ
M;7HO\O\ (^5PTL0M854_5[_^!*_XGNW[-O[2GPD\'?'#PM\7-*UK3X=0T+68
M;@R7UN(9O*)VS(K.!G=$SH=IY#5^TW[0_P )K+]HC]G_ ,2?"R+6#:?\)#HL
MD>GZE" WV:<C?!..?FVR!&QGD#'>OYXM:_9I\;R6YO?#FHZ7K%O_  R6DBQM
M(/I]W\F-?T#_ +$WB35/%W[(/PUUS789([Z3P3IR7RR8W":.W2-\X]64FOA>
M*Z-.BZ.)HRU3MYJVJ_4_5> \16Q$<1@\1"R:3\G?1_A;J?B+KNE_M/\ PTU:
M\TK5;;3M>>QGD@N[>2W\FXA>-BK*5&WY@01@;NE4;3]H_0I96T#X@^!KRPDZ
M3Q21"51_O(X5@/P-?47_  5S27]F?]KV34;SPMO\.^.;(:M975FV&CN =ETA
M5N';S,2\%<"8#'%>&V&L?"[XOZ=]C1K/4OERUM<)MFB]\'##ZCCWKZ+"UXXC
M"PKRAI))W6GY::/0^4Q6$G@\=4PT*OO0;5I:W[>>JL^IS<7@S]G?XF#=H,]G
M;W4@PJV,OV:0'_KDP /_ 'S6#XD_95UJSW3>%/$$-TJ\K;WBF*3Z;AE3^.VK
M_C3]ER AK_P#J6UAR+&^;(/^[)V]@V?]ZN.LO&OQ=^%NH?V-=:A=6YC_ .7/
M4%\R,KZKG/'NI_&N^ES25Z52_DSS:WLXNU>E;SC_ %^9^\W_  3X^*NN?&+]
MD/P3XH\6VS0ZW::2NF:U'),)'-U:GR&D)!()D"++])!7K'BWQ+I/@SPKJ7B_
M7[E8;'2K":\O)FZ)%&A=V_!0:_.O_@A9^UP_CGQ!XK^ /B.QAM;J2U36]-,4
MQVS,I6&<!3R#M,)QD\!C7TM_P5,\9?V-^R1KG@6RU:2SO/&4B:/#-"PW1Q-^
M\F;'=3&C1G_KJ/45^7X[+94\[>&:LI27R3U_!?D?M66YM"KPZL6GS.,6G?=R
MBK:^;=OO/Q1^+_Q%/QU^,/B;XL^(M1N+:\\2:Y<Z@PN$,J1+)(62/<OS (NU
M!A3@**R[;P'K]Y"UUH4,6J1XRW]FS"5U'J8A^\7\5%=!XL^ /CGPL&N;*V75
M+5>?.LU/F >\?7\MWUKD[7S[699;>1HY8S\LB,59#]>QK]9ING[-*D]%H?AU
M6-7VKE63NW=OU_ :+:2"9H)HF213AHW7#*?<=JFBBVCD5UFF?%'4)HDL?'.C
M6NOVJ\ WBXN$_P!V8#=^>:]/_9R_9J^'?[4/QC\.?#_X?^)+BSDU+4HQJ.EW
MV-Z6JG?.R-G^&)7(Y;G .,UG5Q$</!SJJR6K>Z.C#X.6(J1A1=Y-I)/1Z_@_
MO/TM_P"".?[/?_"DOV0=-\3ZM8>5K'CBX.M79>/#K;LH2V3/=?*42#T,S5]8
M56T?2M/T+2;71=*M%@M;.W2"VA0?+'&BA54>P  JS7XQC,3/&8J=>6\FW_DO
MDM#^@<!A*> P=/#PVBDO7N_F]3F?C1_R1[Q8/^I:O_\ TG>OYZ8X2>"O-?T,
M?&49^$'BH?\ 4MWW_I.]?SXP1J%SBOM>"_X5;UC^I\!Q]_&P_I+\T$46/ZU8
MCB]12Q19_AJ=(RW"CGO7VK9^>K42),-C'-?MW_P3M&W]B;X<C_J7E_\ 0WK\
M38H@G4<U^V?_  3QX_8I^'0_ZE]?_0WKY#C#_<:?^+]&?=<"?\C"I_@_5'L]
M%%%?G9^I!1110 4444 %%%% !1110 4444 %%%% !7YU_P#!S!X1\2^./V'/
M"V@>%=)EN[J3XH6/RQK\J#[%??,S=%7W) K]%*^-?^"XLT%K^R'I=U=3K'''
MXWM7DDD8!546EX223T %>ED\W3S2E)=&>/Q!3C4R6O%[.)^)WPH_98\*>#5C
MUGQCY.L:@OS[)%S;0GV4_?\ JPQW %+\3_VIO"/@XOHO@N*+6+Z/Y6D1O]%A
M/IN'W_HO'^T.E>:_'7]H35_'M_-X<\*7TMOH4>4/EY5[WG[S=]GHOXGG@>8A
M<<_I7ZU3PLJCYZ[OY'X16QU.BG3PZMY_U^9N^-_B7XV^(EW]I\6:]-,BMF*U
M5ML,7^Z@XS[]3W)KW3_@F-\$_$_B[]L+X5^.KE39Z7I_Q$T>:.:5.;IDOHCM
MC'<9&"W0<@9(('F_[._P3?XGZXVLZ[&RZ+I\@^T#D?:9.HB!],<L1VP."V1]
MP_LM76B^&_VD/AE',\5K;CQ[HMM;1JNU=S7L*HB@>^  *RS#$*G0E2IKH_EH
M:Y5AI5L53K57]I?/5?@?O0.E% HK\8/Z*"OB;_@OQXPT+P+^P-)XBU_PXFJ1
MQ^,M-6&TD1"#(?-VM\P(&,'G&1VK[9KX=_X.#/ NN_$;]@-?#&@"(32>.M+=
MI)GVK&H$V6/<]>@!->ED_*\TH\VW,CQ>(G-9'B'#?D=ON/PM\6_M3_$_Q"&M
MM'N(=&MMNT1V*9DV_P#71LD?50M8WASX9?%KXLW0U.#3K^\63[VI:E,WEGZ2
M2'YOHN3[5[W\./V9_ '@A([W5K4:QJ"\_:+R,>6K?[,?('U.XYZ$5UWC/QUX
M2^'>DC4_$^J1VT?2&-1NDE(_A11R?Y#N17ZY]:IT_=H0_K\S\ ^IU:D>?$U-
M/7^D>1^%OV,X4"R^-O%[%N]OID>!_P!]N/\ V6O6O@C\*O@3\,?B]X.N;G3=
M.AN9/%.G?9Y-6N!)([_:8P"BN>N?[H%>3ZC\:?C%\6KJ33?@_P"%YK*S5MKZ
M@RJ7'/4R-\D?'898>M1_!+P;X+T+]H7P7??$7XIMJNK'QEINZRT93<-YGVN+
M&^=R% ]0!GTJ*L<14IR]I.VCT6^W6VPZ-3"TJT'1IWU7O/1;]+[_ "/Z@5VX
M^44M-C^[3J_%#^F#X[_X+NWGB&#_ ()Q>*+'PQJRV-U?:SI,/VIM06U"*+V*
M0_O6=0N?+QUYSCN:_ J\\&75PS2>*/BSH8;JPDU66[/_ )"1\_G7]"?_  60
M\):+XQ_8<UC3_$&EQ7EK#KFFS20S [3BX50>/=A[5^2>F^!O!.B*%TOPGIMO
MC_GG91J?SQ7Z1PEB%1RN22^T_P EU_X!^*^(>#EBL\BV].2/?O+II^9\K6?@
M7PC<8$'Q(AN/^O+0[N3^:+6A#\+=&E&8M=UJ7C.8?"DY _\ 'J^KX88HA^[0
M+CIM&*FSC@O7U'U^71/[U_D?!_V33ZM?<_\ Y(^4$^$VFM\JZMKB^[^$KC'Z
M,:9+\*]*AYE\8/#_ -?GAV]3_P!!C:OK,=>6J5%P/F;\,]*?]H5.WY?Y$_V/
M1Z/\'_\ )'R39^"[NS<?\(_\4]$#CHJZI):,/^_J)BNDTF3]I+1@)M!\17VI
M*O*_8]6BU)?^^0\G\J^CKK2=+U!/*OM-MYU/\,T*N/U%8M]\#_A9JK>;=>";
M*.3_ )Z6JF!OKF,K3^OQE\<?P3_R%'*)Q_AR:]&U_F>1V'[1/Q@\*2>3XS\-
MQR?-S]OT^2VD^G&!_P".UUNF?M)?#7QA MAX^\'-#&>\]NEW"/S&[\E-=+-\
M$]0LX?+\&_$O6;%?^?2^=;RW(]-DG;\37*^(OA?XMT_?-XI^%&CZ_!WO?#LC
M6=S]2B\$^P0UFYX6KTL_)V_/3\3MIT,?16LFUYJZ^]7?X(V8?@O\!OB1 UWX
M,U)()&^9AI=X,I]8GSM'MA:YOQ'^R?XMTT--X6U>WU)>T,W[F3]25/YBL*W\
M'> M3O?^*-\=W6AZE&V$L?$,9A9']!.G Y]0#79:=\2?C3\)WCA^(.BOJFFG
MA;QF#;AZK,F0?HXR?:C_ &B'\.=_*6__  36*PM5?O*=O[T=EZVV^:/-VT[Q
MY\-]1Q.NJ:-<EN&5WAW_ $(P''TR*_H _P""6>L:GX@_X)__  QUG6;UKBZF
MT%_,FDQEL7$H'3V %?DKX4\:^ ?BWI;VUFT-TNW_ $C3KV(;T'NIR"/<9'O7
M[!?\$\M%TWP_^QAX!T?1[40VL&DR"&%6)" W$IP,Y/>ODN+L1[7 PC*-I*7Z
M,^_X!PBP^95)0G>+@_\ TJ)YQ_P5_P#V7/#7[1'[+\WB;4EDCO\ P/<'5+:[
M@95=+8C9<@E@1L"8E.?^>(Z=:_'7Q%^SEXT\.E=8\&Z@NI1K\\,EJWESJ/[P
M&>3_ +IR?2OZ+/$?A_1_%?A^^\+^(;%;JPU*SEM;ZVD^[+#(A1T/L5)%?SU_
M&7P]\2OV.OV@_%?P1BU:1XO#NMRV\,%TNZ*XMR=\,FW^'?$R-\I!YJ>#\76J
M49X=2^'5)]4]_P ?S-./L!0IXBGBW#2?NMK=-;>MU^13\#_M!>*_#%R-"\?V
M$UY'"P2222,I=0_4-C?_ ,"PWO7K:0^ _BSX;!*VNI6;_=_OPMC_ +ZC;\C^
M%<?HOC7X6_&ZWCT3QCI$=IJFW;#YCX.?^F4HQ_WR?R:L?5_A7\0/@_J3>*OA
M_J$EY:+S,H7YPG]V1.CK[CD=<+UKZ>I&G4G:W)+\&?'T95*4+W]I#\5ZH]%_
M9>35OV._VL_!?QOT^_>;P[::PEOK=PRY>UL;C,,[2!?O*J2,X8#&4&0._K?_
M  7,_:'U'Q5^U/HOPN\):])%;^!]%!EDL[HK_IEWMED!VGG$2V_7U;U.?*OA
ME\1='^)>CO)%$(;J)=M[9LV[;D?>&?O(?_K'WX_]ISP3XBUSQ->?%ZXU":^D
MU"97UAYCEDDP%#C_ &" !['V/'''#PJ9I"O67O1BX^M]OP<OO/2EB:E+):F&
MP[]R<E+T2W_%1]+,J^!/VCM0MGCT_P <V7VB/I]OM5"R#W9>A_#!]C7<ZSX!
M^&OQ?TW^V]/>$S./EU&QP) WI(.Y]0PR/:OGN.,#I6QX4\2Z_P"#M1&J^'M1
M>WEZ,HY609^ZPZ$?Y&*]*IA8WYJ;Y7^!Y='%RY>2JN:/X_U_5S2\<_"?Q/X
ME\W4(?M%DS8COH5.SV#?W#]>#V)K[Y_X(*_L_+=:SXK_ &D]:L/DM(AH>A22
M1\>8VV6X=3ZA?*3([2./6OG3X:^.]*^*FC-:262?;-HCO=/9=P;/&5!^\K>G
M4'CT)_7;]D_X%:+^SA\!?#_PIT;3TMVL[4S7ZQL6!NI6,DQ!/)&]B!_L@#M7
MR_$F95*>7NA)6E)V^2U?Z+YGV7">4TJV:+$Q=X05_F]%^K]4>C4445^=GZH<
MW\8R/^%1>*L_]"W??^D[U_/W#">#7]!GQ+LX]0^'>O6,Q.R;1;J-]OH86!K\
M%_&OP[UKP+?BUOQYUO)S:WB+A91Z'T;U'Y9%?=\&SBH5H]VOU/S?CVG*52A+
MHE+]#!2/(VJ*L11A12H@4<5/# 2>17VQ^?V[!% 7.:_:S_@GJ,?L7?#P#_H
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MY<._E8_[L2^D4:XSC!<\G!;CYUGN/$/CCQ(+B]N);[4=1N%4-(<L[L< >PZ
M#H*_7L+1<HW6BZOJ_3LC^=\PQ7+))J\NBZ+U[O\ !?GUNJ^/OBC\:=1B\&>&
M[)K>S8;;?1-(7RH(XQW<\?*.Y8A0>@%>Z?LJ?LL:!X9^+W@[6?&-W_:%_'XH
MTYTMX6*P1,+F,CT9R#ZX'L:T/A-\+-(^%WAN/2[.))+R50VH7H7YI7] >R#H
M!^)Y)KO/!GBC2/!OQ$\*ZIJ\I56\5Z;#$B_>DD:ZC 4>_?V )[5CB,0Y4W"D
MK*SVZG1@\'&-:-7$.\KK?9?U_P ,?ODHP,9HI%/%+7XN?TL>#_\ !3/P[:^)
M/V'_ ![#>SB*&QTZ+4))&E,81;:XBG8ELC "H2><8SGBOPW\0?M&_"'PL[P6
M%W)J4RMAO[/M]P)_ZZ-A6^H)K^A7XZ?##3/C9\&/%GP>UI]EKXH\.WNE3R;<
M[%G@>+=CN1NS^%?@1X7_ &>?!'PNNY-)N?#"RZK93-#=3ZDHDD25#M88/RKA
M@1P!]37WG"-;#_5:L)WNFG9>:_X!^2^(F'Q7UZA5I62E%IM^3OM_V\<2/VE/
M&NO#=X'^#6H7<;?=F?S)%/\ W[3 _P"^JGB^(O[3=X/,M/A%9Q]P)D<']917
MK<4> $ X_A%3HFWJ*^M]M2CM37S;9^>_5J\OBJOY)+]&<'\(/$OQN\0_%CPO
MX5^)/P\AL]"U3Q!9V>LZA8H?,MK66=$DE4^8Z@JC%N01QR*_6-?^"+?P"/S?
M\+3\8?\ ?RT_^,5^;:J^X%..^X=J_6?]@7]LO0/VD/AO:^&O$FJQQ^-M&LUB
MUBSD8!KU5&T7<?\ >##!<#[CDC&"I/S/$E?'4Z<*V&]U*ZE;\'U_JQ]SP7@\
MKK5:F'QJYY.SBY>6Z5K>3^\X!?\ @B]\ E.1\4?&'_?RT_\ C%/'_!&;X"#K
M\3_&'_?RT_\ C%?8(HKX_P#MC,_^?K_#_(_2%PWD<=J"_'_,^05_X(V_ 9?^
M:G>+O^_EK_\ &:D'_!'/X#C_ )J9XN_[^6O_ ,9KZZ)P,UYC^U%^UA\*_P!E
M#X<WWCSXA7KW%Q#9R36.A6#*UY?LJYVQH2,#U=L*/7. ;IYEFU>HJ<)MM[+3
M_(BMDN0X:DZE2E%16K;O_F?/7B[_ ((9_LK^.;;R/$?C#Q1,^W$=RLEJLR?1
MQ#G'MT]165X,_P""#WP&\#,;?2OCU\0)K)AB33[R6RD@=>XV_9P!]1@UU'[$
M?_!57P;^T7XFC\"?$VVL-!U+7[J23P;=02-]GOX\DBS<O]RZ11CD@2[25"D%
M*^P*Z,5F&?8&?L:M1KRTM\M/Z9RX+*>%\RIK$4*47YZI^CU_I:[,^$M7_P""
M ?[+-WK<?B'0/BEXXT6ZCDW@Z7<6B+N]0# =OT7 /I7V'\$?A5IWP/\ A3HO
MPHTG6KO4;?1+3R(KZ^5!-,-S-N;8JKG+=@!7545Y^*S+'8R"A7FY);7/6P>4
M9;E]1SPU-1;T=K_\,!K\J_\ @X'_ &<O[(\;^$_VGM#LI/)UBW.B:](L?R)<
M1 R6SD_WGC,J\]H%K]5*\;_;[_9[C_:=_92\7?"NWM$DU*33S>:$S?PWT'[V
M'![;BOED_P!UVKHR3'?V?F5.JWI>S]'H_NW^1R\19=_:F3U:*7O6O'U6J^_;
MYG\^\408<\?UKU;X0_':\T>2'P[XWNFFL_NP:A(2SP>@<_Q+[]1[CIYFL#JV
MR1&5E.&4CE3Z?6IXX-W45^P5:<*T;2/P7#U*E&?-%_\ !/H37OAQ]BUR+XD?
M#F...^C^>ZLHV AU&,_>7C@,PZ-T)P3SS78VQL=?TE7:#S+>Z@PT4R8RK#E6
M!Z'L0>E>6_LZ_$.9I?\ A -8G9AM+:;(Q^[@9:+Z8Y'IR/05[#'&JC"+WKP\
M1&I3ERSZ;/R/IL+[.I3YX:)[KSZ_UU/F;Q_X(F\">++G0W#-#GS+.1OXXC]T
M^^.5/NIK)4<X%>V?M'>&8[WPK;^)(T_?6%P$9@.L<AQC\&V_F:\9ABYYKU,/
M4]M14GN>1BJ/L:SA';<^EO\ @DK\$K_XN_MDZ#>LD@TSPO%)K&J,J_(RQX$4
M3=B&F:,[3U"MZ5^U0Z5\7?\ !$S]G_\ X5O^S=>?%_5[()J7CB_\VW9OO"P@
M+1Q#';,GG/[JRU]HU^8\38WZYFDDMH>ZOEO^.GR/V#A'+_J.3Q;^*?O/Y[?A
M9_,****^?/IS(\?.J>!M:9V"K_9-QDGM^Z:OR5USPUI7BC1I-#U>W\R&9>O\
M2-V93V(]?Z5^KWQ@P?A-XH!_Z%V^_P#1#U^1WP<\22>*/!5O+=2;KFS_ -'N
M&[DJ!M;ZE2,GUS7UG#<9>QJ371K]3XGBR495Z--]5+]#Q?Q7X.O_  9K\VB:
MC\VWYH9@.)(ST8?R/H0:IHG85[A\9_!Z>(O"3:E!%_I6G9EC8=6C_C7\OF^J
M^]>+1Q%N2*^\P];VU.[W/SG$4/8U>5;=!(XL]!7[0?\ !/X$?L:?#X?]0%?_
M $-Z_&F&':.5-?LQ^P&,?L<?#\?]0%?_ $-J^8XO_P!RI_XOT9]=P/IF%3_!
M^J/8****_/C]."BBB@ HHHH **** "BBB@ HHHH **** "OA'_@XQ^&=UX^_
MX)I:SK]E923R>$_$^F:L5C7)6,RFU=OH%N<GT STK[NKE?CC\)?"_P >O@YX
MH^"GC6-FTGQ5H-UI=^8_O)'-$T9=?]I<[@>Q KKP&(^IXVG6_EDG\KZ_@<&:
M8/\ M#+:V&6\XM+U:T_$_D?5<<UZ[^QO=0P?$J]@=L--H\@C'J1+&<?EG\JY
M?]H+X%>._P!F?XU>)/@1\3-/-OK7AG5)+*Z7!VR@'*3)GK'(A613W5P:J?"+
MQ>OP_P#B)I?B>X8K;Q3;+S S^Y<;7..^ <_45^VU.6OAFX:W5UY]4?S53<L+
MC$JBLXNS7;H_N/LP"OE;]J/5KG5?C+J%G,WR:?!!;PKZ*8Q(?_'I#7U7%)'-
M&LD+AD8!E93D,#T(]17RW^U-H%SI/Q?NK^0?N]2M8;B-OH@C(_./]17G9?\
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M (*'W7Q.\"^&_A/^T%K&WQ)+IMO'I6OW4G_(4.P ),QZ3GLQ_P!83@_/]_\
M+G3/ QUG2[7X/>&9_,L;6Z%QXKU>+_5O+Q^XC/\ $1^FT$]"*]CLK.*QABM[
M2,1QPJJQ*O\   , #Z 5QYQA,/F%'DGO=M/JM$OQWL>CP_CL9E>(52F]$DI+
MI+5O\+V3[^6A^W(;/(HKXM_X)R_M\:]\6/&3?LP>-M+U76M6TG33<1^)K6U:
M6."%0,17LF?E?LLA^]D*WS<M]I*25R:_,\9@ZV!KNE46N_JNC/V3+\?A\RPR
MK47IL_)K=?(*#THHKE.T_"__ (*D_LZ_\,]?ME>)M.TZS:/1_$DO]O:-E<+L
MN69I4&.,).)5 [*%KY]2//2OUL_X+H_L^#Q]^S[I?QTT:R#:AX)U$)?2*/F;
M3[DK&WUVS>2WL"YK\FTB4#I7Z]D..^O97";?O+W7ZK_-6?S/POB3+?[.SBI!
M*T9>\O1_Y.Z^1-HU[=:)JEKK%DVV:UG2:/\ WE.:^L+&6.\M8[V$_NY8U=?<
M$9%?)\<3R-L5&Y.%7UKZPT.Q;3M&L[!QEK>UCC_[Y4"M<P^R^NICE;;YETT.
M?^,R1GX9:J)!_P LX\9]?-3%>/\ P>^&.M?&#XG^'_A;X=C9KS7M6ALH2JYV
M;W :0^RKECZ!37IG[0^N16/A.'05?][J%P"1Z1H0Q/\ WUM_6O?/^"'_ , 5
M\7_&;6OCUK-AOL_"=E]DTMY ?^/ZX!!=?4I") ?3SE-<U3%?V?E=2N^E[>NB
M7XG=2P?]I9Q2PRZVOZ;O\#]-? 7@S1?AWX*TGP'X<MA#I^BZ;#8V4?\ =BB0
M(OXX4?C6O117Y-*4I2NS]JC&,8J*V04444BCG?B\,_"?Q1Q_S+M[_P"B'K\8
M?V;[UX]4U+2B?EDMTF5?]I6V_P#LWZ5^SWQ=_P"24>)_^Q=O?_1#U^+_ .SI
M;.WBZ\DQ\JZ<P/XNE?:<+V^IXB_>/ZGP/%]_KV&MVE^AZ^8%G0Q2KE6&&7U!
MKYTU/2QI>L7>E_\ /M=21?\ ?+$?TKZ41 !TKY_\7A)?&.K2QCY?[2GQCO\
MO#7TV!;YI(^1S**Y8F7#!CFOV0_8(&/V// (Q_S E_\ 0VK\>8H=W.*_8C]@
MWC]D'P$,?\P-?_0VKQ>+G_L5/_%^C/H."(VQ]1_W?U1ZY1117Y^?I@4444 %
M%%% !1110 4444 %%%% !1110 4$9&*** /@G_@M#_P2*M?V[O"L?QI^"L%O
M9_%+P]8^3#'(RQQ>(+1<L+61S@)*I)\J0G'S%&PI#)^!/C/P1XQ^&_BN_P#
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M6WU31?!^FV&HVZR*XCGAM8XY%#*2&PRD9!(/:O ?^"SG[+7QH_;!_8U;X/?
M;PU#JVO'Q587WV6?4(K9?)B$N]M\K*O&X<9R:_)\OJ48YW3G-KEY[MO:U^Y^
M_9Q1Q,N%ZM.E%N?L[)):WMLEW/Q6L?B=\(?V@/#_ /PB?C+&F7C-NCCN9@NR
M3'WH9<;2>V#@GI@BO,OB7\ /&?PZ=[Z"W;4M+'*WULG*+_TT3DK]>5]^U?2
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MO_(^?8H<#(K]@/V$@5_9$\!@_P#0#7_T-J^!X_\ @F)^V*OS'X<VG_@\M?\
MXY7Z(_LJ>!/$WPR_9Y\*^ ?&5BMMJFEZ8(;R!95D"/N8XW*2#U[&O%XFQF%Q
M&$A&E-2?-T:?1GT/"6!QF%QDY5J<HIQZIKJNYZ#1117Q)]\%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !117-_$'XP_"SX4?9?\
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M8M-?>M :<=&%%%%;""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"W2/]E7QQ;I]V/PW,%_!:\K_ ."3:@?LZ:HV?^9NN!_Y+VU>K?MC@M^RWXZ
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M97*R>Y4&OU-C<.@=6R#SD=Z^6/VX/V:-*L?V+M+T7PQ:JTWP\AMYH9%CR\L
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MF6*R^A.A@*G)[.,TXIS4??E"+U47]ST72RBO+W8J3NS\\?\ @GG^S/\ "O\
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M[7"A/V7O'2C^'PO=?^BS7:>#MO\ PB.EE!\O]FP8S_US%<7^UT,_LP^.^/\
MF6;K_P!%FOK:F1Y/DO#>+>!P\*7/1ES<L5&]H2M>V]KNWJS+VDYU%S.^IY#_
M ,$EE(_9WUIB/^9RN,?^ MK63_P5'^.OC/PII^A_!'P1J$UJWB*&2;5)+:3;
M)+#O$:0 CD*[;MWJ%QT+ [/_  28_P"3<M8_['*Y_P#26UKS3_@I2$?]KGX?
MI(-RG3+$,K=#G4):_-L=B\5A/!7"JA-Q=2-.#:T?+*=G]ZT?DV=$5S8QW/3/
MAI_P2V^ NE^";6V^(ZZEJVM2VZM?7<.I/!'%(1RL:I@;0> 6W$XSWP/-_"WP
M9^-_[$_[5MG#\+=$\0^(O ^K20#4)+>PDF3[+(^QA-Y:[?.A.65@ 2,< .RU
M]SC;CBD(0=:^[Q'AOPY&.'EET/JU6C*,HU()<SMNI/[2EUYKOY-IXK$5->;5
M,\H_;<^*?B'X/?LVZ]XN\)7+V^I,(;2SNHQS;M+($,@]"%+8/8XKY^_8G_86
M^#WQ=^#]K\8_BZU]K5]KEQ</';C4)(DA"3/&2Q1@SNS(6))[@8R"3]8_&GX4
M:!\;OAEJWPP\2R21VNJ6^SSX<;X)%8,DBY[JP!QWQCO7QYX>_9T_X**?LNO<
M:)\$_$$.KZ*;@R1PVMQ;M')G^+R;G!C8CJ$/XGK7@<:9?6AQ?0S+'8&>,P<:
M3BH0BJG)4<KN3IM^]>-E?]4BZ,OW+C&5G<]:;_@F1\%=(^(>C^.O ?B/7]#B
MTV\$\]A:Z@S&4KRH28GS(N>I!.1D#:>1](("!@U\5Z%_P4,_:(^#GC2S\*_M
M8_")+.SNCS=6UD]O.J;L&5<LT<RCN%Q]>@K[.TK4K+6--M]7TVY6:VNH5FMY
MHSE9(V *L/8@@U]'P3B^#\1]8CDE'V,U).K3<7"47:RO!Z)6VY=-^IG6596Y
MW?L6****^\, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>trvi-20260806.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-08-06T10:14:52.9027+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.trevitherapeutics.com/20260806" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:trvi="http://www.trevitherapeutics.com/20260806" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" namespace="http://fasb.org/us-gaap/2026"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" namespace="http://xbrl.sec.gov/dei/2026"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation" id="DisclosureDocumentAndEntityInformation">
        <link:definition>75000 - Disclosure - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation" xlink:href="trvi-20260806.xsd#DisclosureDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 06, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001563880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  06,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Trevi Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0834299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">195 Church Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">16th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-2499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TRVI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="trvi-20260806.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Disclosure - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="trvi-20260806.htm">trvi-20260806.htm</File>
    <File>trvi-20260806.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "trvi-20260806.htm": {
   "nsprefix": "trvi",
   "nsuri": "http://www.trevitherapeutics.com/20260806",
   "dts": {
    "inline": {
     "local": [
      "trvi-20260806.htm"
     ]
    },
    "schema": {
     "local": [
      "trvi-20260806.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 23
   },
   "report": {
    "R1": {
     "role": "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation",
     "longName": "75000 - Disclosure - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_12ac05c8-0279-4f76-b996-3bdae692fb3f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "trvi-20260806.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12ac05c8-0279-4f76-b996-3bdae692fb3f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "trvi-20260806.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.trevitherapeutics.com/20260806/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-26-337974-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-337974-xbrl.zip
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MWC ,^X=9(M0;NJ[_<#=,\]HT5'7 Z.__<Z%R77./<1[8OXWJ9[%\F*2_[*K
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M+9&2L-]T8S[^^-U^LY\-PH__!5!+ P04    "  (H09=&S?PZ&\)  !R;P
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M4.+!A^<5!/S#C_OQ*Y8&,[#7!)/EL\G;FB^+OUCJ1]C]@@,4/(]9MW09X>D
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M]8M29ARTE/,Q3L6ZP),5QC*@0H+GEXS<?^.WZ\W"%K,>C6].ZH?E)X53@X\
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M^ CR%\5:.P@4;S\+"[-A!!L>-GG)*I\1-OS&/ZH?3_W;IAY&8H%DOF'S3D;
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M5#:?$4=*Y2EC:G36R<$(V4>1LBC6=+9IO^)BS7H3P2V,LUXDG#<-G@S;OG&
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MC\=\(&Q*:HWW4Y%T>73#)]HDI;YZV8O#R0]_>_5RF(ZB'_X?4$L! A0#%
M  @ "*$&78V3G,C/%   8]X  !$              ( !     '1R=FDM,C R
M-C X,#8N:'1M4$L! A0#%     @ "*$&71LW\.AO"0  <F\  !$
M     ( !_A0  '1R=FDM,C R-C X,#8N>'-D4$L! A0#%     @ "*$&7>^"
M/L>$(0  UU$"  \              ( !G!X  '1R=FDM97@Y.5\Q+FAT;5!+
4!08      P # +L   !-0      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>trvi-20260806_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="trvi-20260806.xsd" xlink:type="simple"/>
    <context id="C_12ac05c8-0279-4f76-b996-3bdae692fb3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563880</identifier>
        </entity>
        <period>
            <startDate>2026-08-06</startDate>
            <endDate>2026-08-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_010c86df-6375-402b-8fff-cf24a014cb3b">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_443e78a6-97ae-49b2-b079-3daa0f3f52bc">0001563880</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_88b72521-18a8-42e3-8cf5-3f60712d086c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_d6b0b947-29aa-4329-8de7-623a95b84ed1">2026-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_c8d13245-a1d4-4295-bc51-6f00603701fb">Trevi Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_3fe60d15-d48e-41b6-86bb-720ea8f22ab2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_f0dbe610-88f6-4139-98c0-a5c4d67188ab">001-38886</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_b98e9ed8-2493-4bde-b1c0-51f24a046f08">45-0834299</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_90a2c64b-12eb-4b80-b27a-e6cd914396cd">195 Church Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_1359e679-dc46-4432-bce7-1b3be6c375ff">16th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_f0529c0c-8305-46f2-8f14-3f47d2b35d6a">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_224947f6-127f-4003-a913-250aeb75e47c">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_a63acce3-2eac-4093-971e-eaf0f60875bd">06510</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_2d76ada8-873d-4de4-b51f-d65c12d77b80">(203)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_5c98a87b-6b3b-479b-9000-4f6ce639c9d5">304-2499</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_69161118-9ceb-4a6a-8b95-feeee4a2cafc">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_4868c66a-146a-4992-a381-51a71c78ee0f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_bcfe3931-80d5-4bb7-8699-d74cd7cea4e5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_1e54c2c1-0d3c-4566-93e6-013d823a4d5b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_26fdd185-e141-45ee-8f10-deb61b17ccf9">Common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_7536ceda-08b6-4dfa-bcac-029d866409af">TRVI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_4a816194-d16a-4034-9994-146c06aa86f0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_12ac05c8-0279-4f76-b996-3bdae692fb3f"
      id="F_0e60ef11-a67e-40c3-b30c-3d14afe3c103">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
